Table 1 Patient characteristics and outcomes
From: Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients
Variable | No AKI (n = 72) | AKI (n = 21) | P value |
|---|---|---|---|
Age (years) | 50 (28, 65) | 66 (57, 71) | 0.002 |
Female gender | 22 (31 %) | 5 (24 %) | 0.79 |
APACHE II score | 15 (11, 19) | 19 (14, 24) | 0.01 |
Body weight (kg) | 78 (70, 90) | 88 (79, 93) | 0.06 |
Baseline creatinine (µmol/l) | 82 (69, 91) | 83 (71, 88) | 0.69 |
True baseline creatinine available | 52 (72 %) | 12 (57 %) | 0.28 |
Time admission–enrolled (h) | 12 (5, 23) | 8 (3, 14) | 0.10 |
Time from first biomarker analysis to AKI diagnosis (days) | N/A | 1.0 (0.5, 1.5) | |
Comorbidity | |||
Diabetes | 6 (8 %) | 5 (24 %) | 0.12 |
Cardiovascular disease | 20 (28 %) | 11 (52 %) | 0.06 |
COPD/asthma | 5 (7 %) | 2 (10 %) | 0.65 |
Gastrointestinal/liver disease | 2 (3 %) | 3 (14 %) | 0.07 |
Any malignancy | 11 (15 %) | 3 (14 %) | 1.0 |
Admission diagnosis | |||
Neurologic | 4 (6 %) | 1 (5 %) | 0.03 |
Respiratory | 14 (19 %) | 6 (29 %) | |
Cardiovascular | 2 (3 %) | 5 (24 %) | |
Trauma | 37 (51 %) | 7 (33 %) | |
Gastrointestinal | 3 (4 %) | 1 (5 %) | |
Sepsis | 12 (17 %) | 1 (5 %) | |
Outcome | |||
ICU length of stay, days | 5 (3, 9) | 4 (3, 8) | 0.72 |
ICU mortality | 4 (6 %) | 2 (10 %) | 0.62 |
30-day mortality | 8 (11 %) | 4 (19 %) | 0.46 |